Short-term Intensive Immunosuppression: A Randomized, Three-arm Study of Intravenous Pulse Methylprednisolone and Cyclophosphamide in Macular Serpiginous Choroiditis.

PURPOSE: To compare the efficacy of pulse cyclophosphamide with pulse dexamethasone in acute macular serpiginous choroiditis (SC). METHODS: A total of 30 patients with macular SC were prospectively randomized into three treatment groups: group D (pulse dexamethasone); group C (pulse cyclophosphamide); and combination (pulse group DCP) administered for 3 days. Macular SC was defined as any active lesion involving/threatening macula. RESULTS: A total of 30 patients were enrolled, with 10 patients in each group. Lesions completely healed at median duration of 2 weeks in each group, with significant improvement in visual acuity compared with pretreatment levels (p<0.05). Pulse cyclophosphamide was most effective in faster healing of lesions compared with other groups. There was no difference in gain in visual acuity between any of the groups (p = 0.32). CONCLUSIONS: Cyclophosphamide may be an effective treatment modality for acute macular SC, though it may not have a long-term effect on disease relapse.

Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy.

PURPOSE: To evaluate safety and efficacy of intravenous pulse cyclophosphamide (CyP) in acute macular serpiginous choroiditis (SC). METHODS: Patients with acute macular SC with lesions threatening and/or involving fovea were enrolled. All patients received CyP (1 g/m2) for 3 days followed by high-dose oral steroids (1.5 mg/kg) tapered over 6 months and monitored for visual acuity, response to treatment and systemic side effects. RESULTS: Eight patients (seven unilateral and one bilateral) with median age of 27 years (range: 13-40 years) were recruited. Mean visual acuity at presentation was 0.71 ± 0.35 logarithm of the minimum angle of resolution while postpulse visual acuity was 0.40 ± 0.32. Final mean visual acuity at 1-year was 0.31 ± 0.23 (P ≤ 0.05). Three eyes had recurrence and 3 patients developed transient hair loss with no other adverse effect. CONCLUSION: Intravenous CyP provides rapid resolution of lesion activity and thereby helps in maintaining good functional acuity.

Novel occurrence of axenfeld: Rieger syndrome in a patient with blepharophimosis ptosis epicanthus inversus syndrome.

Blepharophimosis ptosis epicanthus inversus syndrome (BPES) is a complex eyelid malformation characterized by the classical tetrad of blepharophimosis, telecanthus, ptosis, and epicanthus inversus. It has been reported to be associated with other ocular anomalies such as euryblepharon, strabismus, nystagmus, amblyopia, microphthalmos, lacrimal drainage apparatus abnormality, extra ocular muscle abnormalities, microcornea, trabecular dysgenesis, optic nerve hypoplasias, and colobomas of the optic disk. We describe a case of BPES with Axenfeld-Rieger syndrome, a neurocristopathy characterized by maldevelopment of the anterior segment with predisposition to development of glaucoma. Interestingly, both syndromes are caused by mutations in the same class of genes, namely the winged-helix/forked transcription factors (FOX) involved in a variety of developmental processes.

Evaluating eye drop instillation technique in glaucoma patients.

AIM: To evaluate the technique of eye drop instillation in glaucoma patients. METHODS: Seventy patients with primary open-angle glaucoma or primary angle-closure glaucoma, self-administering topical antiglaucoma medications for at least 6 months were evaluated. All patients instilled a tear substitute in 1 eye using the same technique they used for instilling antiglaucoma medications at home. The parameters that were recorded included time taken to instill the first drop, number of eye drops instilled, drop contact location, any contact with the tip of the bottle, and closure of the eyelids or tear duct after drop instillation. RESULTS: The mean age of the patients was 54.1±10.0 years. The mean time taken to instill the first drop was 14.8±3.7 seconds (range, 8.7 to 23.5 s). The mean number of drops squeezed from the bottle per instillation was 1.8±1.2 drops (range, 1 to 8 drops). In 22 patients (31.43%), the eye drops fell on the eyelids or cheek. Fifty-three patients (75.7%) touched the tip of the bottle to the globe or periocular tissue. Twenty patients (28.57%) closed eyes after instilling drops and 4 patients (5.7%) occluded the punctum. Only 6 patients (8.57%) were able to correctly instill the eye drops (squeeze out 1 drop and instill it into the conjunctival sac without bottle tip contact). CONCLUSIONS: Nearly, 9 of 10 glaucoma patients were unable to instill eye drops correctly. This may be an important cause of unintentional noncompliance in glaucoma medical therapy.

Comparing homatropine and atropine in pediatric cycloplegic refractions.

PURPOSE: To compare cycloplegic efficacy of homatropine and atropine in pediatric refractions and derive a regression formula to calculate refraction findings for both agents. METHODS: Children between the ages of 4 to 10 years with refractive error underwent cycloplegic refraction with 2% homatropine and 1% atropine by retinoscopy and automated refraction. Refractive data were compared by the use of power vector analysis. Primary outcome measures were spherical equivalent (SE), astigmatic components of refractive error (J(0) and J(45)), overall blur strength of refractive error, and residual accommodation. RESULTS: A total of 63 children with refractive error were enrolled (mean age, 6.7 ± 1.6 years). Compared with homatropine, atropine uncovered significantly greater hyperopic SE in patients with hypermetropia (4.2 ± 2.5 D [atropine] vs 3.5 ± 2.3 D [homatropine]; P < 0.001) as well as myopia (-1.8 ± 1.4 D [atropine] vs -2.1 ± 1.4 D [homatropine]; P < 0.001). Overall blur strength was significantly greater with atropine (3.1 ± 2.1 [atropine] vs 2.9 ± 1.9 [homatropine]; P = 0.003). Homatropine had a significantly greater residual accommodation (1.8 ± 0.4 D [atropine] vs 3.1 ± 0.5 D [homatropine]; P < 0.001). A regression formula was derived. CONCLUSIONS: Of the 2 cycloplegic agents, atropine yielded more consistent results than homatropine; however atropine had a relatively slow onset and prolonged effect. Our regression formula may make it possible to derive atropine-like results while using the clinically more versatile homatropine.